Preclinical CRO Market is Set to outsourcing Growth at a CAGR of 7.2% Over 2030 :

Pune, India, May 2022, MRFR Press Release/- Market Research Future has Published a Cooked Research Report on the Global Preclinical CRO Market.


Market Highlights


The Global Preclinical CRO Market is estimated to be valued at USD 9.1  Billion by 2030 and is expected to register a CAGR of 7.2% during the forecast period.


The toxicology testing segment is expected to lead the market and register a substantial CAGR to reach USD 9.1 Billion by the end of 2030. Increasing demand for testing new drugs and chemicals and vigorous growth in the pharmaceutical and biopharmaceutical sectors are expected to drive the market growth. However, the bioanalysis and drug metabolism and pharmacokinetics (DMPK) studies segment is projected to exhibit the highest CAGR of 8.96% from 2019 to 2024. New technological developments by various companies to provide better services to pharmaceutical companies is driving the growth of the segment.


Americas accounted for the largest market share of 40.7% in 2018, and the regional market is projected to register a CAGR of 7.2% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Indian market is projected to exhibit the highest growth rate of 7.2% during the forecast period of 2022-2030. 


Segment Analysis


The global preclinical CRO market has been segmented on the basis of services, therapeutic area, end user and region. On the basis of service, the market has been divided into the toxicology testing, bioanalysis & bioanalysis, and drug metabolism and pharmacokinetics (DMPK) studies and others. The toxicology segment held the majority market share in 2018. However, bioanalysis & bioanalysis and drug metabolism and pharmacokinetics (DMPK) studies are expected to be the fastest-growing owing to the new technological developments by various companies to provide better services to pharmaceutical companies.


Explore In-depth Details: Preclinical CRO Market Research Report


Market Players


Market Research Future (MRFR) recognizes IQVIA (US), PAREXEL International Corporation (US), Envigo (US), Charles River (US), Eurofins Scientific (Luxembourg), ICON PLC (Dublin), PRA Health Sciences (US), Medpace (US), Laboratory Corporation of America Holdings (US), Pharmaceutical Product Development, LLC (US), WuXi AppTec (China), MD Biosciences (US) as the key players in the global preclinical CRO market.


Regional Analysis


Geographically, the global preclinical CRO market has been segmented into North America, Europe, Asia-Pacific, and the Middle East & Africa. As per MRFR analysis, the Americas was the largest market for the preclinical CRO in 2018 and is expected to remain dominant during the review period. Europe accounted for a significant market share and is projected to be the second-largest market during the forecast period. The increasing outsourcing activities in Europe are driving the growth of the preclinical CRO market in the region. Germany accounted for the largest market share of 24.7% in 2018, and the country-level market is projected to register a CAGR of 6.69% during the forecast period.


Key Findings of the Study:



  • The Global Preclinical CRO Market is projected to reach over USD 9.1 billion by 2030 at 7.2% CAGR during the review period of 2022-2030.



  • Americas accounted for the largest market share with North America being the major contributor to the growth of the market.



  • The toxicology testing segment is projected to register the highest CAGR of 7.2% during the forecast period owing to the increasing demand for testing new drugs and chemicals.

  • Key manufacturers are adopting geographic expansions, corporate acquisitions, and product launches as growth strategies. Moreover, they are focusing on e-commerce for distribution.